Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 3/20 | 0.67 |
| ▸ | KEAP1 | Q14145 | 7/20 | 0.61 |
| ▸ | NFE2L2 | Q16236 | 7/20 | 0.61 |
| ▸ | EP300 | Q09472 | 4/20 | 0.61 |
| ▸ | CCR1 | P32246 | 2/20 | 0.51 |
| ▸ | CCR2 | P41597 | 2/20 | 0.51 |
| ▸ | CCR4 | P51679 | 2/20 | 0.51 |
| ▸ | HKDC1 | Q2TB90 | 3/20 | 0.49 |
| ▸ | HK1 | P19367 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | BLM | P54132 | 3/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.46 |
| ▸ | G6PD | P11413 | 2/20 | 0.46 |
| ▸ | CFTR | P13569 | 1/20 | 0.46 |
| ▸ | FABP4 | P15090 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2780397 | 0.91 | BRAF (0.69) | BRAFKEAP1NFE2L2EP300HKDC1 | |
| SCHEMBL2781467 | 0.88 | KEAP1 (0.76) | BRAFKEAP1NFE2L2EP300HKDC1 | |
| SCHEMBL2777007 | 0.88 | BRAF (0.68) | BRAFKEAP1NFE2L2EP300HKDC1 | |
| SCHEMBL2778910 | 0.88 | BRAF (0.70) | BRAFKEAP1NFE2L2EP300HKDC1 | |
| SCHEMBL2778927 | 0.87 | BRAF (0.69) | BRAFKEAP1NFE2L2EP300HKDC1 | |
| SCHEMBL2779521 | 0.83 | BRAF (0.74) | BRAFKEAP1NFE2L2EP300HKDC1 | |
| SCHEMBL2239377 | 0.80 | BRAF (1.00) | BRAFKEAP1NFE2L2EP300HKDC1 | |
| SCHEMBL13509739 | 0.71 | STAT3 (0.66) | BRAFKEAP1NFE2L2EP300HKDC1 | |
| SCHEMBL13509712 | 0.71 | STAT3 (0.57) | BRAFKEAP1NFE2L2EP300HKDC1 | |
| SCHEMBL13509686 | 0.69 | MCL1 (0.71) | BRAFKEAP1NFE2L2EP300HKDC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142917-A1 | PROTEASOME INHIBITORS HAVING CHYMOTRYPSIN-LIKE ACTIVITY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2012-06-07 | — | — | US | claimed |
| WO-2010102286-A2 | PROTEASOME INHIBITORS HAVING CHYMOTRYPSIN-LIKE ACTIVITY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2010-09-10 | — | — | WO | claimed |
| US-8466157-B2 | Proteasome inhibitors having chymotrypsin-like activity | UNIVERSITY OF SOUTH FLORIDA (US) | 2013-06-18 | — | — | US | disclosed |
| US-8466157-B2 | Proteasome inhibitors having chymotrypsin-like activity | UNIVERSITY OF SOUTH FLORIDA (US) | 2013-06-18 | — | — | US | disclosed |
| US-8466157-B2 | Proteasome inhibitors having chymotrypsin-like activity | UNIVERSITY OF SOUTH FLORIDA (US) | 2013-06-18 | — | — | US | disclosed |
| US-20120142917-A1 | PROTEASOME INHIBITORS HAVING CHYMOTRYPSIN-LIKE ACTIVITY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120142917-A1 | PROTEASOME INHIBITORS HAVING CHYMOTRYPSIN-LIKE ACTIVITY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120142917-A1 | PROTEASOME INHIBITORS HAVING CHYMOTRYPSIN-LIKE ACTIVITY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| WO-2010102286-A2 | PROTEASOME INHIBITORS HAVING CHYMOTRYPSIN-LIKE ACTIVITY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142917-A1 | PROTEASOME INHIBITORS HAVING CHYMOTRYPSIN-LIKE ACTIVITY | PSMB4, PSME4, PSMB1 | BRAF 2332/4885KEAP1 352/4885NFE2L2 1376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.